Cor Vasa 2026, 68(4):448-454 | DOI: 10.33678/cor.2026.018

Circulating microRNA-29 Reflects Remodeling-Related Ventricular Changes in Ischemic Dilated Cardiomyopathy.

Mark Onsy Dimitrya, Osama Louisb, Solaf Ahmed Kamelc, Eman Mahmoud Hassanc, Rasha Nazihc, Sally M. Hafezc, Amira Fawzy Solimand, Eman Awadallahc
a Cardiology Unit, Department of Internal Medicine, National Research Center, Cairo, Egypt
b Heart Failure Unit, National Heart Institute, Cairo, Egypt
c Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt
d Department of Clinical and Chemical Pathology, National Heart Institute, Cairo, Egypt

Background: Fibrotic remodeling is a hallmark of ischemic dilated cardiomyopathy (IDCM). Among microRNAs (miR) implicated in extracellular matrix regulation, miR-29 has been experimentally linked to collagen expression and transforming growth factor-β / mothers against decapentaplegic homolog 3 related signaling. However, its circulating profile in human IDCM and its relationship with ventricular structure and function remain insufficiently characterized. The purpose of this study is to quantify plasma miR-29 in patients with IDCM and examine whether circulating miR-29 aligns with established echocardiographic indices of adverse ventricular remodeling.

Methods: This study included 46 angiographically confirmed IDCM patients and 30 healthy individuals. Plasma miR-29 expression was assessed using RT-qPCR with miR-103 normalization. Echocardiographic measurements included ejection fraction (EF), left-ventricular end-diastolic diameter (LVEDD), and left-ventricular end-systolic diameter (LVESD). Group comparisons, Spearman correlations, ROC analysis, and multivariable regression were performed. © 2026, ČKS.

Keywords: Extracellular matrix, Echocardiographic indices, Ischemic dilated cardiomyopathy, miR-29, Ventricular remodeling

Received: January 19, 2026; Revised: January 19, 2026; Accepted: February 24, 2026; Prepublished online: August 19, 2026; Published: August 31, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dimitry MO, Louis O, Kamel SA, Hassan EM, Nazih R, Hafez SM, et al.. Circulating microRNA-29 Reflects Remodeling-Related Ventricular Changes in Ischemic Dilated Cardiomyopathy. Cor Vasa. 2026;68(4):448-454. doi: 10.33678/cor.2026.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 1.10.2026

    References

    1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368-378. Go to original source...
    2. Shen NN, Wang JL, Fu YP. MicroRNA expression profiling in heart failure. Front Cardiovasc Med 2022; 9:856358. Go to original source...
    3. Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. J Clin Invest 2017;127:3312-3319. 454 Circulating miR-29 in Ischemic Dilated Cardiomyopathy
    4. Del Buono MG, Moroni F, Montone RA et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction. Curr Cardiol Rep 2022;24:1505-1515. Go to original source... Go to PubMed...
    5. Ravassa S, López B, Treibel TA, et al. Cardiac fibrosis in heart failure. Mol Aspects Med 2023;93:101194. Go to original source... Go to PubMed...
    6. Poddi S, Lefter CL, Linardi D, et al. Myocardial fibrosis: assessment, quantification, prognostic significance, and antifibrosis targets: a state-of-the-art review. J Cardiovasc Dev Dis 2025;12:192. Go to original source... Go to PubMed...
    7. Zhu L, Wang Y, Zhao S, et al. Detection of myocardial fibrosis: where we stand. Front Cardiovasc Med 2022;9:926378. Go to original source...
    8. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Nat Rev Cardiol 2021;18:143-158.
    9. Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells 2020;9:276. Go to original source... Go to PubMed...
    10. Varzideh F, Kansakar U, Donkor K, et al. Cardiac remodeling after myocardial infarction: functional contribution of microRNAs to inflammation and fibrosis. Front Cardiovasc Med 2022;9:863238. Go to original source...
    11. Makkos A, Ágg B, Petrovich B, et al. Systematic review and network analysis of microRNAs involved in cardioprotection against myocardial ischemia/reperfusion injury and infarction. Free Radic Biol Med 2021;164:274-283. Go to original source... Go to PubMed...
    12. Sandau US, Wiedrick JT, McFarland TJ, et al Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers. Sci Rep 2024;14:2148. Go to original source...
    13. D'Amato A, Penna C, Leucker TM et al. MicroRNA and heart failure: novel promising biomarkers to aid in diagnosis and prognosis. J Clin Med 2024;13:7560. Go to original source... Go to PubMed...
    14. Charidemou E, Felekkis K, Papaneophytou C. From natriuretic peptides to microRNAs: multi-analyte liquid biopsy horizons in heart failure. Biomolecules 2025;15:1189. Go to original source... Go to PubMed...
    15. Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis, including collagens. J Biol Chem 2011;286:5615-5623.
    16. Liu Y, Afzal J, Vakrou S, et al. Differences in microRNA-29 and pro-fibrotic gene expression in cardiac fibrosis models. Front Cardiovasc Med 2019;6:170. Go to original source...
    17. Qin W, Chung AC, Huang XR, et al. TGF-β/Smad3 signaling promotes renal fibrosis by suppressing miR-29. J Am Soc Nephrol 2011;22:1462-1474. Go to original source... Go to PubMed...
    18. Roderburg C, Urban GW, Bettermann K, et al. MicroRNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011;53:209-218. Go to original source...
    19. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. J Am Soc Echocardiogr 2015;28:1.e14-39.e14. Go to original source...
    20. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays. RNA 2008;14:844-852. Go to original source... Go to PubMed...
    21. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines. Clin Chem 2009;55:611-622. Go to original source...
    22. Leancă SA, Crișu D, Petriș AO, et al. Left ventricular remodeling after myocardial infarction. Life (Basel) 2022;12:1111. Go to original source... Go to PubMed...
    23. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs as biomarkers and extracellular communicators. Circ Res 2012;110:483-495. Go to original source... Go to PubMed...
    24. Peterlin A, Počivavšek K, Petrovič D. The role of microRNAs in heart failure. Front Cardiovasc Med 2020;7:161. Go to original source...
    25. Searles CD. MicroRNAs and cardiovascular disease risk. Curr Cardiol Rep 2024;26:51-60. Go to original source... Go to PubMed...
    26. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs. Nat Cell Biol 2007;9:654- Go to original source... Go to PubMed...
    27. Sohel MH. Extracellular/circulating microRNAs. Achiev Life Sci 2016;10:175-186. Go to original source...
    28. Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a as a biomarker of hypertrophy and fibrosis. J Am Coll Cardiol 2014;63:920-927. Go to original source...
    29. Mylavarapu M, Kodali LSM, Vempati R, et al. Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy. World J Cardiol 2025;17:106123. Go to original source...
    30. Li M, Zhang J. Circulating microRNAs as biomarkers. Biomed Res Int 2015;2015:730535.
    31. Li C, Meng X, Wang L, Dai X. Focus on the TGF-β/Smad signaling pathway. Front Pharmacol 2023;14:1092148. Go to original source... Go to PubMed...
    32. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden death in dilated cardiomyopathy. JAMA 2013;309:896-908. Go to original source... Go to PubMed...
    33. Wang X, Yu S, Xie L, et al. The role of the extracellular matrix in cardiac regeneration. Heliyon 2024;10:e41157. Go to original source...
    34. Feng H, Hu W, Liu Y, et al. Macrophages in ventricular remodeling and heart failure. Front Immunol 2025;16:1682294. Go to original source... Go to PubMed...
    35. Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes. JACC Cardiovasc Imaging 2009;2:34-44. Go to original source... Go to PubMed...
    36. Li S, Wang Z, Zhang Y, et al. T1 mapping and extracellular volume fraction in dilated cardiomyopathy. JACC Cardiovasc Imaging 2022;15:591-603. Go to original source... Go to PubMed...
    37. Parvan R, Hosseinpour M, Moradi Y, et al. Diagnostic performance of microRNAs in heart failure. Eur J Heart Fail 2022;24:2212-2225. Go to original source...
    38. Sucharov CC, Neltner B, Pietra AE, et al. Circulating microRNAs identify early phenotypic changes. Circ Heart Fail 2023;16:e010291. Go to original source... Go to PubMed...
    39. Glinge C, Clauss S, Boddum K, et al. Stability of circulating blood-based microRNAs. PLoS One 2017;12:e0167969. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content